These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 11119792

  • 1. Cyclosporine formulations: is there really a difference?
    Masri MA, Stephan A, Barbari A, Rizk S, Kelany H, Kamel G.
    Transplant Proc; 2000 Nov; 32(7):1468-9. PubMed ID: 11119792
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB, Martin JE, Schroeder TJ, First MR.
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [What significance has the C(2) value in the treatment with cyclosporin A?].
    Pham VV, Stichtenoth DO, Frölich JC.
    Dtsch Med Wochenschr; 2004 Mar 26; 129(13):706. PubMed ID: 15026970
    [No Abstract] [Full Text] [Related]

  • 8. Bioavailability and pharmacokinetics of cyclosporine formulations: Neoral vs Sandimmune.
    Choc MG.
    Int J Dermatol; 1997 Dec 26; 36 Suppl 1():1-6. PubMed ID: 9466213
    [No Abstract] [Full Text] [Related]

  • 9. Verapamil improves Sandimmune immunosuppression, reducing acute rejection episodes.
    Citterio F, Serino F, Pozzetto U, Fioravanti P, Caizzi P, Castagneto M.
    Transplant Proc; 1996 Aug 26; 28(4):2174-6. PubMed ID: 8769192
    [No Abstract] [Full Text] [Related]

  • 10. Acute allograft rejection following conversion to a new cyclosporine formulation in pediatric renal transplant patients.
    Crocker J, Renton K, Wade A, McLellan H, Acott P.
    Transplant Proc; 1998 Aug 26; 30(5):2002-5. PubMed ID: 9723369
    [No Abstract] [Full Text] [Related]

  • 11. Generic substitution for cyclosporine: what should we be looking for in new formulations?
    Johnston A, Holt DW.
    Transplant Proc; 1998 Aug 26; 30(5):1652-3. PubMed ID: 9723228
    [No Abstract] [Full Text] [Related]

  • 12. Lessons from the Neoral Global Database for renal transplantation.
    Helderman JH.
    Transplant Proc; 1999 May 26; 31(3):1659-63. PubMed ID: 10331036
    [No Abstract] [Full Text] [Related]

  • 13. Influence of drug formulation on utilization and outcomes: Neoral and monitoring by sparse sample area under the curve.
    Belitsky P, Mahalati K, West K, Sketris I.
    Transplant Proc; 1999 May 26; 31(3):1667-8. PubMed ID: 10331038
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. The impact of cyclosporin formulation on clinical outcomes.
    Holt DW, Johnston A.
    Transplant Proc; 2000 Nov 26; 32(7):1552-5. PubMed ID: 11119831
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Absorption of cyclosporine Neoral early after liver transplantation: is it possible to abandon intravenous cyclosporine A application?
    Haller GW, Winkler M, Bechstein WO, Oldhafer KJ, Ringe B, Maibücher A, Färber L, Pichlmayr R, Neuhaus P.
    Transplant Proc; 1996 Aug 26; 28(4):2239-40. PubMed ID: 8769211
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
    Løkkegaard H, Asmundsson P, Clausen P, Dieperink H, Hansen JM, Heaf J, Jensen SB, Kornerup HJ, Madsen S, Pedersen EB, Poulsen JV, Rasmussen K.
    Transplant Proc; 1996 Aug 26; 28(4):2199-201. PubMed ID: 8769199
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.